| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLP2 |
| Uniprot No | Q04941 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-152aa |
| 氨基酸序列 | MADSERLSAPGCWAACTNFSRTRKGILLFAEIILCLVILICFSASTPGYSSLSVIEMILAAIFFVVYMCDLHTKIPFINWPWSDFFRTLIAAILYLITSIVVLVERGNHSKIVAGVLGLIATCLFGYDAYVTFPVRQPRHTAAPTDPADGPV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PLP2重组蛋白的3篇参考文献示例：
1. **文献名称**：Structural and Functional Analysis of the PLP2 Proteinase of SARS-CoV
**作者**：Lindner HA, et al.
**摘要**：该研究解析了SARS冠状病毒PLP2蛋白酶的三维结构，揭示了其通过去泛素化活性抑制宿主天然免疫反应的分子机制，为抗病毒药物设计提供了结构基础。
2. **文献名称**：Expression and Characterization of Recombinant PLP2 from MERS-CoV
**作者**：Báez-Santos YM, et al.
**摘要**：报道了利用昆虫细胞表达系统高效表达MERS冠状病毒PLP2重组蛋白的过程，并证实其具有木瓜蛋白酶样水解活性和去ISG化修饰功能，为酶活抑制实验提供了材料。
3. **文献名称**：PLP2 as a Therapeutic Target: Screening of Inhibitors against Coronavirus Papain-like Protease
**作者**：Chen X, et al.
**摘要**：通过高通量筛选发现了靶向PLP2蛋白酶活性的小分子抑制剂，验证了其在细胞模型中抑制病毒复制的效果，提示PLP2可作为抗冠状病毒药物开发的潜在靶点。
**Background of PLP2 Recombinant Protein**
The PLP2 (papain-like protease 2) recombinant protein is a key viral enzyme studied primarily in the context of coronaviruses (CoVs), including SARS-CoV and SARS-CoV-2. PLP2 belongs to the papain-like protease family, a class of cysteine proteases critical for viral replication and pathogenesis. It is encoded within the non-structural protein 3 (nsp3) region of the coronavirus genome, which undergoes autoproteolytic processing to release mature viral enzymes.
Functionally, PLP2 plays a dual role: it cleaves viral polyproteins to generate functional non-structural proteins essential for viral replication, and it disrupts host innate immune responses by deubiquitinating (DUB activity) or deISGylating host proteins involved in antiviral signaling pathways (e.g., interferon regulatory factors). This immune evasion mechanism enhances viral survival and contributes to pathogenicity.
Recombinant PLP2 is produced via genetic engineering, typically expressed in bacterial (e.g., *E. coli*) or eukaryotic systems, followed by purification to study its structural, enzymatic, and interaction properties. Its crystal structure reveals a catalytic triad (Cys-His-Asp/Asn) and a ubiquitin-binding domain, providing insights into substrate specificity and inhibitor design.
Research on PLP2 recombinant protein focuses on antiviral drug development, as inhibiting its protease or DUB activity could block viral replication and restore host immunity. It also serves as a tool for studying virus-host interactions and screening therapeutic compounds. Despite challenges in selectivity and toxicity, PLP2 remains a promising target for broad-spectrum coronavirus therapies, especially in light of emerging variants and pandemic preparedness efforts.
(Word count: 249)
×
